Polymer-free drug eluting stents result in lower in-stent late loss

Polymer-free drug eluting stents result in lower in-stent late loss compared to Paclitaxel-eluting stents with polymers 

Results of the NEXT Clinical Trial Reported at TCT 2011

San Francisco, CA --Researchers have found that polymer-free amphilimus-eluting stents in de novo coronary artery lesions showed a significantly lower in-stent late loss at six months compared to paclitaxel-eluting stents with permanent polymers.

Results of the NEXT trial were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. NEXT is a prospective, randomized trial comparing a polymer-free amphilimus-eluting stent to a paclitaxel-eluting stent.

The risk/benefit balance of coronary drug-eluting stents is still suboptimal, and the safety of coating polymers, which hold and release the drug over time, remains uncertain. Researchers sought to demonstrate the non-inferiority of polymer-free amphilimus-eluting stents versus permanent-polymer paclitaxel-eluting stents in de novo native coronary artery lesions. The primary endpoint was six-month angiographic in-stent late loss within a non-inferiority scope. Late loss is the difference between the diameter of a stented segment post-procedure compared with the follow-up angiogram.

A total of 323 patients were enrolled, with 162 randomized to amphilimus-eluting stents and 161 to paclitaxel-eluting stents. In-stent late loss was significantly lower with amphilimus-eluting stents (0.14±0.36 mm vs. 0.34±0.40 mm, P<0.0001 for non-inferiority, P<0.0001 for superiority). Clinical endpoints (cardiac death, myocardial infarction, target lesion revascularization or stent thrombosis) up to 12 months did not differ significantly.

“These results are encouraging evidence that support the use of polymer-free stents, but further studies are warranted to prove that this potent polymer-free stent can improve the risk-benefit balance of coronary drug-eluting stents,” said Didier Carrié, MD, PhD, the principal investigator of the trial. Dr. Carrié is Professor of Medicine, Cardiology at the University of Paul Sabatier and the Head of Hemodynamics and Angioplasty Section at Rangueil Hospital in Toulouse, France.

The NEXT trial is funded by CID. Dr. Carrié reported no financial relationship with the company.

About CRF and TCT

The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies, drugs and therapies in interventional cardiovascular medicine.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of the Cardiovascular Research Foundation. TCT gathers leading medical researchers and clinicians from around the world to present and discuss the latest developments in the field.

Source: Cardiovascular Research Foundation

Polymer-free drug eluting stents result in lower in-stent late loss

EMBARGOED UNTIL FRIDAY, NOVEMBER 11, 2011 11 30 AM PST  2 30 PM Eastern >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Polymer free drug eluting stents result in lower in stent late loss compared to Paclitaxel eluting stents with polymers  Results of the NEXT Clinical Trial

Comments